356 related articles for article (PubMed ID: 15961765)
21. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma.
Saso R; Kulkarni S; Mitchell P; Treleaven J; Swansbury GJ; Mehta J; Powles R; Ashley S; Kuan A; Powles T
Br J Cancer; 2000 Jul; 83(1):91-4. PubMed ID: 10883674
[TBL] [Abstract][Full Text] [Related]
22. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A
J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418
[TBL] [Abstract][Full Text] [Related]
23. Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience.
Smith RE
Clin Breast Cancer; 2003 Oct; 4(4):273-9. PubMed ID: 14651772
[TBL] [Abstract][Full Text] [Related]
24. Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.
Rosenstock AS; Niu J; Giordano SH; Zhao H; Wolff AC; Chavez-MacGregor M
Cancer; 2018 Mar; 124(5):899-906. PubMed ID: 29236294
[TBL] [Abstract][Full Text] [Related]
25. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
Knoop AS; Knudsen H; Balslev E; Rasmussen BB; Overgaard J; Nielsen KV; Schonau A; Gunnarsdóttir K; Olsen KE; Mouridsen H; Ejlertsen B;
J Clin Oncol; 2005 Oct; 23(30):7483-90. PubMed ID: 16234514
[TBL] [Abstract][Full Text] [Related]
26. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.
Colović M; Suvajdžić N; Janković G; Tomin D; Colović N; Fekete MD; Palibrk V
Biomed Pharmacother; 2011 Aug; 65(5):319-21. PubMed ID: 21775097
[TBL] [Abstract][Full Text] [Related]
27. Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy.
Kuoppala T; Mäenpää J; Tomas E; Puistola U; Salmi T; Grenman S; Lehtovirta P; Fors M; Luukkaala T; Sipilä P
Gynecol Oncol; 2008 Aug; 110(2):190-5. PubMed ID: 18534669
[TBL] [Abstract][Full Text] [Related]
28. [Adjuvant epirubicin and cyclophosphamide followed by weekly paclitaxel for Japanese women with node-positive breast cancer: a multi-institutional feasibility study].
Saimura M; Mitsuyama S; Anan K; Tanaka M; Shimada K; Hirose N; Ogawa S; Tamaki N; Tomisaki S; Tamura K
Gan To Kagaku Ryoho; 2008 Sep; 35(9):1519-23. PubMed ID: 18799904
[TBL] [Abstract][Full Text] [Related]
29. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
[TBL] [Abstract][Full Text] [Related]
30. Early occurrence of acute myeloid leukemia following adjuvant radiotherapy and higher cumulative dose of cyclophosphamide in carcinoma breast.
Srivastava A; Murari M; Datta NR
Indian J Cancer; 2004; 41(4):178-80. PubMed ID: 15659873
[TBL] [Abstract][Full Text] [Related]
31. Acute myeloid leukemia and myelodysplastic syndrome following breast cancer: increased frequency of other cancers and of cancers in multiple family members.
Padmanabhan A; Baker JA; Zirpoli G; Sait SN; Ford LA; Moysich KB; Baer MR
Leuk Res; 2008 Dec; 32(12):1820-3. PubMed ID: 18468682
[TBL] [Abstract][Full Text] [Related]
32. Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer.
Calip GS; Malmgren JA; Lee WJ; Schwartz SM; Kaplan HG
Breast Cancer Res Treat; 2015 Nov; 154(1):133-43. PubMed ID: 26450505
[TBL] [Abstract][Full Text] [Related]
33. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients.
Faurschou M; Sorensen IJ; Mellemkjaer L; Loft AG; Thomsen BS; Tvede N; Baslund B
J Rheumatol; 2008 Jan; 35(1):100-5. PubMed ID: 17937462
[TBL] [Abstract][Full Text] [Related]
34. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
Ogasawara T; Yasuyama M; Kawauchi K
Am J Hematol; 2005 Jun; 79(2):136-41. PubMed ID: 15929101
[TBL] [Abstract][Full Text] [Related]
35. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
Papaldo P; Lopez M; Marolla P; Cortesi E; Antimi M; Terzoli E; Vici P; Barone C; Ferretti G; Di Cosimo S; Carlini P; Nisticò C; Conti F; Di Lauro L; Botti C; Di Filippo F; Fabi A; Giannarelli D; Calabresi F
J Clin Oncol; 2005 Oct; 23(28):6908-18. PubMed ID: 16129844
[TBL] [Abstract][Full Text] [Related]
36. Leukemia following chemotherapy for breast cancer.
Curtis RE; Boice JD; Moloney WC; Ries LG; Flannery JT
Cancer Res; 1990 May; 50(9):2741-6. PubMed ID: 2328500
[TBL] [Abstract][Full Text] [Related]
37. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
[TBL] [Abstract][Full Text] [Related]
38. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).
Freedman RA; Seisler DK; Foster JC; Sloan JA; Lafky JM; Kimmick GG; Hurria A; Cohen HJ; Winer EP; Hudis CA; Partridge AH; Carey LA; Jatoi A; Klepin HD; Citron M; Berry DA; Shulman LN; Buzdar AU; Suman VJ; Muss HB
Breast Cancer Res Treat; 2017 Jan; 161(2):363-373. PubMed ID: 27866278
[TBL] [Abstract][Full Text] [Related]
39. Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial.
Kümmel S; Krocker J; Kohls A; Breitbach GP; Morack G; Budner M; Blohmer JU; Lichtenegger W; Elling D
Crit Rev Oncol Hematol; 2006 May; 58(2):166-75. PubMed ID: 16387512
[TBL] [Abstract][Full Text] [Related]
40. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.
Rouëssé J; de la Lande B; Bertheault-Cvitkovic F; Serin D; Graïc Y; Combe M; Leduc B; Lucas V; Demange L; Nguyen TD; Castèra D; Krzisch C; Villet R; Mouret-Fourme E; Garbay JR; Noguès C;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1072-80. PubMed ID: 16504757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
